Epicrispr Biotechnologies
PrivateLast Round
Series C
Aug 11, 2026
Est. Valuation
$95.14M
Total Funding Raised
$213M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Epicrispr Biotechnologies operates in Healthcare & Life Sciences and is based in South San Francisco, California. Its latest recorded funding round was a Series C round in August 2026.
Epicrispr Biotechnologies is a biotechnology company developing gene-modulating therapies using its proprietary Gene Expression Modulation System (GEMS) to treat a range of genetic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epicrispr Biotechnologies Comparables
Compare Epicrispr Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tune Therapeutics | 84% | |
| Moonwalk Biosciences | 84% | |
| Epigenic Therapeutics | 81% |
For institutional investors. Book with your work email.
Epicrispr Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 11, 2026 | ||||
| Series B | Mar 26, 2025 | ||||
| Series A | Jul 12, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Epicrispr Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series C |
| Horizons Ventures | Series A |
| abrdn Inc. | Series C |
| Ally Bridge Group | Series B |
| Readout Capital | Series C |
| Cormorant Asset Management | Series C |
| Duquesne Family Office | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 11, 2026
Monthly visitors increased 43% MoM.
- Sep 3, 2026
Grew 18% QoQ, from 44 to 52 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 20, 2026
Epicrispr Biotechnologies, Inc. is developing EPI-321, a treatment candidate for facioscapulohumeral muscular dystrophy, using its Gene Expression Modulation System platform to regulate gene expression without directly changing DNA in California.
- hiresOct 20, 2026
Epicrispr Biotechnologies, Inc. appoints Enoch Kariuki, PharmD, to its Board of Directors on Oct 20th '26 as it advances EPI-321 toward pivotal clinical development and expands its gene-modulating medicines pipeline.
- receives_financingOct 19, 2026
Epicrispr Biotechnologies, Inc. receives an $8M grant from the California Institute for Regenerative Medicine on Oct 19th '26 to support its first-in-human EPI-321 trial for facioscapulohumeral muscular dystrophy in California.
- is_developingAug 11, 2026
On Aug 11th '26, Epicrispr Biotechnologies, Inc. is developing EPI-321, an epigenetic medicine in first-in-human testing for facioscapulohumeral muscular dystrophy.
- hiresAug 11, 2026
As part of the financing, Epicrispr Biotechnologies, Inc. is set to appoint Anran Li to its board.
For institutional investors. Book with your work email.
Epicrispr Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Epicrispr Biotechnologies's valuation, stock price, and market status.
Is Epicrispr Biotechnologies a public or private company?
Epicrispr Biotechnologies is a private company.
What is the current stock price of Epicrispr Biotechnologies?
Epicrispr Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Epicrispr Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Epicrispr Biotechnologies worth (valuation)?
Epicrispr Biotechnologies's valuation is estimated at $95.1M based on funding round data.
Can I buy Epicrispr Biotechnologies stock?
Epicrispr Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Epicrispr Biotechnologies's last funding round?
Epicrispr Biotechnologies's most recent funding round was Series C on August 11, 2026.
Who are the main investors in Epicrispr Biotechnologies?
Key investors in Epicrispr Biotechnologies include Janus Henderson Group, Horizons Ventures, Ally Bridge Group, Octagon Capital Advisors.
Will Epicrispr Biotechnologies IPO soon?
No public IPO plans have been announced for Epicrispr Biotechnologies.
How can I track Epicrispr Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Epicrispr Biotechnologies's shares on secondary markets.